Patent ID: 9073981
Filing Date: 2015-07-07
Classification: A61P,C07K,Y02A

Abstract:
1. An isolated human antibody, or an antigen-binding fragment thereof, that neutralizes a dengue virus of serotypes DENV-1, DENV-2, DENV-3, or DENV-4, wherein the antibody does not contribute to antibody-dependent enhancement of dengue virus infection, wherein the Fc region of said antibody or antigen-binding fragment thereof comprises a CH2 L4A mutation, a CH2 L5A mutation, or both, and wherein the antibody, or the antigen binding fragment thereof, comprises the heavy chain CDR1, CDR2 and CDR3 and the light chain CDR1, CDR2 and CDR3 sequences as set forth in (i) SEQ ID NOs: 1-6, respectively; (ii) SEQ ID NOs: 17-22, respectively; (iii) SEQ ID NOs: 33-38, respectively; (iv) SEQ ID NOs: 49-54, respectively; (v) SEQ ID NOs: 67-72, respectively; (vi) SEQ ID NOs: 83-88, respectively; (vii) SEQ ID NOs: 83-85, 99, 53, and 100, respectively; (viii) SEQ ID NOs: 105-110, respectively; (ix) SEQ ID NOs: 121-123, 70 124, and 125, respectively; (x) SEQ ID NOs: 135-139, and 109, respectively; (xi) SEQ ID NOs: 149, 136-139, and 109, respectively; (xii) SEQ ID NOs: 153-158, respectively; (xiii) SEQ ID NOs: 169-174, respectively; or (xiv) SEQ ID NOs: 185-188 37, and 189, respectively.